Ï㽶ÊÓƵ

Mary Steinbach
( out of 66 reviews )

Mary Steinbach, NP

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
Salt Lake City
801-585-2626

  • Mary Steinbach is a board-certified Nurse Practitioner for the Division of Hematology at the Ï㽶ÊÓƵ of Utah Huntsman Cancer Institute, Blood and Marrow Transplant Program. She received her Bachelor of Science in Nursing from the Ï㽶ÊÓƵ of Loyola Chicago and her Doctor of Nursing Practice degree from the Ï㽶ÊÓƵ of Utah. Her early years as a registered nurse motivated her to advance her practice and she is proud to have worked as an NP at Huntsman for almost a decade. Mary’s clinical interests include hematology and more specifically caring for patients with Multiple Myeloma. She has served as a member of the International Myeloma Foundation’s Nurse Leadership Board (NLB) since 2018, working to improve the nurs­ing care and self-care of patients with myeloma. In her role on the NLB, Ms. Steinbach has made valuable contributions to the education of both patients and nurses through educational seminars across the country. Notably, Mary traveled to Abu Dhabi as part of the first stem cell transplant team in that country and she has contributed to several publications in reputable journals including Blood Advances, Seminars in Oncology Nursing, and Leukemia.

    Specialties

    Patient Rating

    5.0 /5
    ( out of 66 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    October 30, 2024
    HUNTSMAN CANCER CENTER

    Easy to talk to. Answers questions completely and thoroughly.

    October 14, 2024
    HUNTSMAN CANCER CENTER

    a true professional i enjoy working with her

    October 14, 2024
    HUNTSMAN CANCER CENTER

    Mary was very professional and did a great job.

    October 13, 2024
    HUNTSMAN CANCER CENTER

    Mary is incredible! She is very knowledgeable, hard-working, kind, patient, and respectful. She knows how to listen and explain things in a way that I can understand them. I am so grateful to have her help.

    September 08, 2024
    HUNTSMAN CANCER CENTER

    Very professional, attentive and friendly.

    September 01, 2024
    HUNTSMAN CANCER CENTER

    Mary Steinbach was knowledgeable, personable, and took time to answer all my questions.

    July 19, 2024
    HUNTSMAN CANCER CENTER

    She seems very knowledgeable and caring. Enjoy having her as part of the Myeloma team giving me care

    July 15, 2024
    HUNTSMAN CANCER CENTER

    Mary was very thorough and all of my testing was ordered and confirmed completed in plenty of time prior to my appointment. She explained things in a way that I could understand them.

    July 07, 2024
    HUNTSMAN CANCER CENTER

    I really like Mary. She is competent, and thorough.

    See More Patient Comments

  • Mary Steinbach is a board-certified Nurse Practitioner for the Division of Hematology at the Ï㽶ÊÓƵ of Utah Huntsman Cancer Institute, Blood and Marrow Transplant Program. She received her Bachelor of Science in Nursing from the Ï㽶ÊÓƵ of Loyola Chicago and her Doctor of Nursing Practice degree from the Ï㽶ÊÓƵ of Utah. Her early years as a registered nurse motivated her to advance her practice and she is proud to have worked as an NP at Huntsman for almost a decade. Mary’s clinical interests include hematology and more specifically caring for patients with Multiple Myeloma. She has served as a member of the International Myeloma Foundation’s Nurse Leadership Board (NLB) since 2018, working to improve the nurs­ing care and self-care of patients with myeloma. In her role on the NLB, Ms. Steinbach has made valuable contributions to the education of both patients and nurses through educational seminars across the country. Notably, Mary traveled to Abu Dhabi as part of the first stem cell transplant team in that country and she has contributed to several publications in reputable journals including Blood Advances, Seminars in Oncology Nursing, and Leukemia.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Midlevel
    Academic Divisions Hematology & Hematologic Malignancies

    Education history

    Doctoral Training Nursing - Ï㽶ÊÓƵ of Utah DNP
    Nursing - Loyola Ï㽶ÊÓƵ of Chicago BSN
    Undergraduate Environmental Geoscience - Boston College B.S.

    Selected Publications

    Journal Article

    1. Luetkens T, Metcalf R, Planelles V, Zheng Y, Larragoite ET, Spivak ES, Spivak AM, Steinbach M, Blaylock RC, Avila SV, Hankey KG, Martins TB, Slev PR, Mannuel HD, Sajadi M, Rapoport AP, Atanackovic D (2020). Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19. Blood Adv, 4(19), 4864-4868. ()
    2. Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D (2017). Elotuzumab as a novel anti-myeloma immunotherapy. Hum Vaccin Immunother, 13(8), 1751-1757. ()
    3. Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T (2016). Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology, 5(11), e1217374. ()
    4. Couriel DR, Ricker H, Steinbach M, Lee CJ (2016). Neurologic Manifestations of Blood Dyscrasias. Hematol Oncol Clin North Am, 30(4), 723-31. ()
    5. Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Krger N, Luetkens T, Atanackovic D (2015). CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother, 11(7), 1606-11. ()

    Review

    1. Hoshina Y, Galli J, Wong KH, Kovacsovics T, Steinbach M, Salzman KL, McNally JS, Lancaster E, Paz Soldn MM, Clardy SL (2022). GABA-A Receptor Encephalitis After Autologous Hematopoietic Stem Cell Transplant forMultiple Myeloma: Three Cases and Literature Review. [Review]. Neurol Neuroimmunol Neuroinflamm, 9(6). ()
    2. Steinbach M, Julian K, McClune B, Sborov DW (2022). Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. [Review]. Ther Adv Hematol, 13, 20406207221100659. ()
    3. Steinbach M, Richards T, Faiman B (2017). Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients. [Review]. Semin Oncol Nurs, 33(3), 254-264. ()

    Letter

    1. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Krger N, Luetkens T (2019). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. [Letter to the editor]. Leukemia, 34(1), 317-321. ()
    2. Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Krger N, Luetkens T, Atanackovic D (2015). Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. [Letter to the editor]. Blood Cancer J, 5, e285. ()

  • News & Podcasts

    Huntsman Cancer Institute News